Overview

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer

Status:
Not yet recruiting
Trial end date:
2024-03-13
Target enrollment:
Participant gender:
Summary
The overall objective of this open-label, nonrandomized, 2-part Phase 1/1b study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101 in a 3 day on/4-day off weekly regimen (3/4 schedule) in participants with advanced and metastatic solid tumors. Each participant in the dose escalation phase will receive a single dose of TACH101 and be followed for 48 hours in the single-dose lead-in period.
Phase:
Phase 1
Details
Lead Sponsor:
Tachyon Therapeutics, Inc.